| Recruiting | Momelotinib in VEXAS Syndrome VEXAS Syndome, Myelo Dysplastic Syndrome | Phase 2 | 2025-11-25 |
| Recruiting | Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) Low-risk Myelodysplastic Syndromes | Phase 1 | 2025-07-22 |
| Active Not Recruiting | Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes Untreated Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2023-12-06 |
| Active Not Recruiting | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) Chronic Myeloid Leukemia | Phase 2 | 2023-10-04 |
| Active Not Recruiting | Venetoclax in Patients With MDS or AML in Relapse After AHSCT MDS, AML | Phase 1 / Phase 2 | 2022-11-23 |
| Recruiting | Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA MDS, Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2022-05-18 |
| Completed | ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML MDS, AML | Phase 2 | 2021-06-22 |
| Completed | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | 2021-05-01 |
| Completed | CPX-351 in Higher Risk Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2020-04-29 |
| Active Not Recruiting | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | 2019-05-14 |
| Active Not Recruiting | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome Myelodysplastic Syndromes, Leukemia Acute Myeloid | Phase 2 | 2019-04-02 |
| Unknown | SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | 2018-11-01 |
| Unknown | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Neoplasm | Phase 1 / Phase 2 | 2018-09-15 |
| Active Not Recruiting | A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS Myelodysplastic Syndromes | Phase 3 | 2018-03-26 |
| Completed | A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory D MDS, Systemic Autoimmune Diseases | Phase 2 | 2017-01-26 |
| Completed | Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk MDS | N/A | 2016-05-31 |
| Active Not Recruiting | French Registry of First-line Treatment of Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia | — | 2015-10-01 |
| Completed | A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients MDS | Phase 1 | 2015-02-10 |
| Completed | Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML MDS | Phase 3 | 2014-10-14 |
| Completed | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia CMML, Thrombocytopenia | Phase 1 / Phase 2 | 2014-08-07 |
| Completed | A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leuke MDS | Phase 2 | 2014-08-04 |
| Terminated | GFM-Acadesine: A Phase I-II Trial of Acadesine SMD | Phase 1 / Phase 2 | 2013-06-01 |
| Terminated | Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Myelodysplastic Syndrome | Phase 2 | 2013-03-01 |
| Unknown | A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS MDS | Phase 1 / Phase 2 | 2013-02-01 |
| Completed | Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS) Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2011-07-05 |
| Withdrawn | Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2011-03-01 |
| Completed | Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes High Grade Myelodysplastic Syndrome Lesions | Phase 1 / Phase 2 | 2010-12-30 |
| Completed | Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. Myelodysplastic Syndromes | Phase 2 | 2010-07-01 |
| Completed | Erlotinib in Higher Risk Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2010-07-01 |
| Completed | Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) Myelodysplastic Syndromes | Phase 2 | 2010-06-01 |
| Completed | Clofarabine in High Risk Myelodysplastic Syndrome (MDS) Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2010-04-01 |
| Completed | Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q Myelodysplastic Syndromes | Phase 2 | 2010-03-25 |
| Unknown | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediat Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | 2009-02-01 |
| Completed | Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermedia Myelodysplastic Syndromes | Phase 2 | 2009-02-01 |
| Completed | Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) Chronic Myelomonocytic Leukemia | Phase 2 | 2008-11-01 |
| Completed | Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2008-05-01 |
| Unknown | Darbepoetin Alpha in Myelodysplastic Syndromes (MDS) Myelodysplastic Syndromes | Phase 2 | 2006-12-01 |
| Unknown | Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] Myelodysplastic Syndromes | Phase 2 | 2006-10-01 |
| Terminated | A Phase II Study of Maintenance With Azacitidine in MDS Patients Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes | Phase 2 | 2006-07-01 |
| Completed | Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2006-06-01 |
| Unknown | Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Anemia in Myelodysplastic Syndromes | Phase 2 | 2004-10-01 |
| Recruiting | Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia Myelodysplastic Syndromes, Leukemia, Myeloid, Acute | — | 2003-07-07 |
| Completed | Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 Myelodysplastic Syndromes | Phase 2 | 2003-01-01 |